Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study

Background and aims: Familial hypercholesterolemia (FH) is an inherited disorder characterized by high levels of blood cholesterol from birth and premature coronary heart disease. Thus, the identification of FH patients is crucial to prevent or delay the onset of cardiovascular events, and the availability of a tool helping with the diagnosis in the setting of general medicine is essential to improve FH patient identification. Methods: This study evaluated the performance of the Dutch Lipid Clinic Network (DLCN) score in FH patients enrolled in the LIPIGEN study, an Italian integrated network... Mehr ...

Verfasser: Casula, Manuela
Olmastroni, Elena
Pirillo, Angela
Catapano, Alberico Luigi
Arca, Marcello
Averna, Maurizio
Bertolini, Stefano
Calandra, Sebastiano
Tarugi, Patrizia
Pellegatta, Fabio
Angelico, Francesco
Bartuli, Andrea
Biasucci, Giacomo
Biolo, Gianni
Bonanni, Luca
Bonomo, Katia
Borghi, Claudio
Bossi, Antonio Carlo
Branchi, Adriana
Carubbi, Francesca
Cipollone, Francesco
Citroni, Nadia
Federici, Massimo
Ferri, Claudio
Fiorenza, Anna Maria
Giaccari, Andrea
Giorgino, Francesco
Guardamagna, Ornella
Iannuzzi, Arcangelo
Iughetti, Lorenzo
Lupattelli, Graziana
Lupi, Alessandro
Mandraffino, Giuseppe
Marcucci, Rossella
Maroni, Lorenzo
Miccoli, Roberto
Mombelli, Giuliana
Muntoni, Sandro
Pecchioli, Valerio
Pederiva, Cristina
Pipolo, Antonio
Pisciotta, Livia
Pujia, Arturo
Purrello, Francesco
Repetti, Elena
Rubba, Paolo
Sabbà, Carlo
Sampietro, Tiziana
Sarzani, Riccardo
Tagliabue, Milena Paola
Trenti, Chiara
Vigna, Giovanni Battista
Werba, Josè Pablo
Zambon, Sabina
Zenti, Maria Grazia
Minicocci, Ilenia
Noto, Davide
Fortunato, Giuliana
Banderali, Giuseppe
Benso, Andrea
Bigolin, Paola
Bonora, Enzo
Bruzzi, Patrizia
Bucci, Marco
Buonuomo, Paola Sabrina
Capra, Maria Elena
Cardolini, Iris
Cefalù, Baldassarre
Cervelli, Nazzareno
Chiariello, Giuseppe
Cocci, Guido
Colombo, Emanuela
Cremonini, Anna Laura
D'addato, Sergio
D'erasmo, Laura
Dal Pino, Beatrice
De Sanctis, Luisa
De Vita, Emanuele
Del Ben, Maria
Di Costanzo, Alessia
Di Taranto, Maria Donata
Fasano, Tommaso
Gentile, Luigi
Gentile, Marco
Ghirardello, Omar
Grigore, Liliana
Lussu, Milena
Meregalli, Giancarla
Moffa, Simona
Montalcini, Tiziana
Morgia, Valeria
Nascimbeni, Fabio
Pasta, Andrea
Pavanello, Chiara
Saitta, Antonino
Scicali, Roberto
Siepi, Donatella
Spagnolli, Walter
Spina, Rossella
Sticchi, Elena
Suppressa, Patrizia
Vigo, Lorenzo
Vinci, Pierandrea
Manzato, Enzo
Tragni, Elena
Zampoleri, Veronica
Dokumenttyp: Artikel
Erscheinungsdatum: 2018
Schlagwörter: Dutch Lipid Clinic Network score / Familial hypercholesterolemia / Genetic testing / Cardiology and Cardiovascular Medicine
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29031499
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/11586/225493

Background and aims: Familial hypercholesterolemia (FH) is an inherited disorder characterized by high levels of blood cholesterol from birth and premature coronary heart disease. Thus, the identification of FH patients is crucial to prevent or delay the onset of cardiovascular events, and the availability of a tool helping with the diagnosis in the setting of general medicine is essential to improve FH patient identification. Methods: This study evaluated the performance of the Dutch Lipid Clinic Network (DLCN) score in FH patients enrolled in the LIPIGEN study, an Italian integrated network aimed at improving the identification of patients with genetic dyslipidaemias, including FH. Results: The DLCN score was applied on a sample of 1377 adults (mean age 42.9 ± 14.2 years) with genetic diagnosis of FH, resulting in 28.5% of the sample classified as probable FH and 37.9% as classified definite FH. Among these subjects, 43.4% had at least one missing data out of 8, and about 10.0% had 4 missing data or more. When analyzed based on the type of missing data, a higher percentage of subjects with at least 1 missing data in the clinical history or physical examination was classified as possible FH (DLCN score 3–5). We also found that using real or estimated pre-treatment LDL-C levels may significantly modify the DLCN score. Conclusions: Although the DLCN score is a useful tool for physicians in the diagnosis of FH, it may be limited by the complexity to retrieve all the essential information, suggesting a crucial role of the clinical judgement in the identification of FH subjects.